C
ould changing up regulatory requirements for Alzheimer’s drugs help give desperate patients new options for treatment?
A group of researchers and patient advocates think so. They authored a paper that argues that the Food and Drug Administration should evaluate Alzheimer’s drugs for efficacy in either cognition or function — but not both.
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
Obviously Klunk never worked in pharma. 30 years of experience has taught me that getting marginally efficacious drugs approved, then charging obscenely high prices before it is concluded that your drug is a dud is a good business model, because everybody who made their six figure bonuses along the way will be long gone by the time the poo hits the fan.
You should point out that this is really a lobbying group: Registered on 03/26/2017 by Connect 4 Strategies, LLC: http://bit.ly/2pBDMdf